Emily R Hankosky

9PUBLICATIONS
12CO-AUTHORS
Behavioural epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Food properties (incl. characteristics and health benefits)Disease surveillanceOptical technology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 29, 2025
Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.

Emily R Hankosky, Jeremie Lebrec, Clare J Lee

|Jun 24, 2025
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.

Naveed Sattar, Luis-Emilio García-Pérez, Angel Rodríguez

|May 05, 2025
Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.

Emily R Hankosky, Xuanyao He, Raleigh Malik

|Mar 14, 2025
Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.

Theresa Hunter Gibble, Chanadda Chinthammit, Jennifer M Ward

|Feb 25, 2025
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.

Emily R Hankosky, Chanadda Chinthammit, Alexandra Meeks

|Nov 06, 2023
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.

Emily R Hankosky, Hui Wang, Lisa M Neff

Pageof 2

Frequent Collaborators

2 joint publications

W Timothy Garvey

2 joint publications

Theresa Hunter Gibble

1 joint publications

Ágnes Benedict

1 joint publications

Kinga Marczell